Overview
Nicoya Lifesciences provides integrated biophysical characterization instruments for biopharma R&D, including Surface Plasmon Resonance (SPR) for label-free interaction analysis, Circular Dichroism (CD) for protein structure, stopped-flow kinetics, and differential scanning fluorimetry (DSF) for stability assessment. Following its 2025 acquisition of Applied Photophysics, Nicoya offers a unified platform combining these technologies to support drug discovery, optimization, and quality control workflows. Their benchtop systems like Alto, Revo, and Chirascan enable high-throughput, reproducible data for biologics developability and mechanism of action studies.
Frequently asked questions
- What biophysical characterization technologies does Nicoya offer?
- Nicoya provides Surface Plasmon Resonance (SPR) via Alto and Revo for kinetics and binding, Circular Dichroism (Chirascan) for protein structure, stopped-flow (SX) for rapid kinetics, and DSF (SUPR-DSF) for stability, integrated post-Applied Photophysics acquisition.
- Which stages of drug development do Nicoya's solutions support?
- Solutions cover discovery screening, candidate optimization, mechanism of action studies, characterization, and quality control for biologics, delivering insights into function, structure, and stability.
- What are the key benefits for pharma and biotech labs?
- Nicoya's benchtop instruments offer high-throughput, publication-quality data at reduced cost and complexity, suitable for academic, biotech, CRO, and pharma teams, with AI/ML-compatible multi-parameter datasets.